These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38214034)

  • 1. Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?
    Hilley P; Wong D; Ma R; Peterson A; De Cruz P
    Intern Med J; 2024 Jun; 54(6):970-979. PubMed ID: 38214034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease.
    Null K; Kumar V; Lissoos T; Luo M
    J Med Econ; 2018 Nov; 21(11):1102-1109. PubMed ID: 30101633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting.
    Afzali A; Ogden K; Friedman ML; Chao J; Wang A
    J Med Econ; 2017 Apr; 20(4):409-422. PubMed ID: 28112566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.
    Harno-Tasihin J; Siregar L; Paajanen M; Arkkila P; Punkkinen J
    Scand J Gastroenterol; 2024 Mar; 59(3):280-287. PubMed ID: 38006219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Events and Compliance Among Inflammatory Bowel Disease Patients Treated With Home- vs Office-Based Biologic Infusions.
    Schmoyer CJ; Sun K; Zack J; Kumar P; Shivashankar R
    Inflamm Bowel Dis; 2024 Sep; 30(9):1529-1535. PubMed ID: 37819840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS].
    Ventress E; Young D; Rahmany S; Harris C; Bettey M; Smith T; Moyses H; Lech M; Gwiggner M; Felwick R; Cummings JRF
    J Crohns Colitis; 2022 Jul; 16(6):911-921. PubMed ID: 34935945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
    Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
    World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration.
    Lee B; Kim M; Kim ER; Hong SN; Chang DK; Kim YH
    Sci Rep; 2024 Oct; 14(1):24347. PubMed ID: 39420116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Fenster M; Ungaro RC; Hirten R; Gallinger Z; Cohen L; Atreja A; Mehandru S; Colombel JF; Cohen BL
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):257-258. PubMed ID: 30910602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
    Qazi T; Shah B; El-Dib M; Farraye FA
    Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial.
    Little RD; McKenzie J; Srinivasan A; Hilley P; Gilmore RB; Chee D; Sandhu M; Saitta D; Chow E; Thin L; Walker GJ; Moore GT; Lynch K; Andrews J; An YK; Bryant RV; Connor SJ; Garg M; Wright EK; Hold G; Segal JP; Boussioutas A; De Cruz P; Ward MG; Sparrow MP
    BMJ Open; 2024 Jul; 14(7):e081787. PubMed ID: 39032928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease.
    Kolehmainen S; Rautakorpi J; Löyttyniemi E; Af Björkesten CG; Arkkila P; Salminen K; Sipponen T
    Eur J Gastroenterol Hepatol; 2024 Oct; 36(10):1193-1201. PubMed ID: 38973514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
    Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study.
    Buisson A; Nachury M; Pereira B; Fumery M
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1127-1129.e2. PubMed ID: 37802269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease.
    Haar GS; Vasudevan A; Curtain CM; van Langenberg DR
    Res Social Adm Pharm; 2021 Aug; 17(8):1420-1425. PubMed ID: 33129684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
    Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
    J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Chetwood JD; Tran Y; Subramanian S; Smith PJ; Iborra M; Buisson A; Paramsothy S; Leong RW
    J Crohns Colitis; 2024 Sep; 18(9):1440-1449. PubMed ID: 38656784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
    Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
    Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.
    Fierens L; Liefferinckx C; Hoefkens E; Lobatòn T; Dreesen E; Sabino J; Ferrante M;
    J Crohns Colitis; 2022 Aug; 16(7):1059-1069. PubMed ID: 35078228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.